Resveratrol prevents atrial fibrillation by inhibiting atrial structural and metabolic remodeling in collagen-induced arthritis rats
- 147 Downloads
Rheumatoid arthritis (RA) causes atrial remodeling that induces the occurrence and maintenance of atrial fibrillation (AF). In this study, we explored the influence of RA on atrial fibrillation and the potential therapeutic effects of resveratrol in a rat model. The following three groups of female Wistar rats (8 weeks old) were used in this study: control, collagen-induced arthritis (CIA), and resveratrol. Rats in the CIA and resveratrol groups were injected twice with type II collagen in Freund’s incomplete adjuvant. Three weeks after the second injection, resveratrol (10 mg kg−1 day−1) was administered for 4 weeks. Subsequently, atrial electrophysiological parameters were measured. Levels of inflammatory factors in the atria and serum were measured. Atrial histopathological changes were assessed using microscopy, and cardiomyocyte apoptosis and fibrosis were assessed using TUNEL and Masson’s staining. Apoptosis-related and fibrosis-related proteins were assessed using Western blotting. Atrial adenosine triphosphate (ATP) and free fatty acid (FFA) levels were tested using ELISA. Glycogen accumulation and metabolism-related protein expression were assessed. AF inducibility and duration were markedly increased in CIA rats and were reduced by resveratrol. CIA also increased the atrial and serum IL-6 and TNF-a levels and induced atrial apoptosis and fibrosis, which were attenuated by resveratrol. Moreover, CIA induced the impairment of atrial energy metabolism by inhibiting the AMPK/PGC-1α pathway, which was reversed by resveratrol. Resveratrol protects against RA-induced atrial structural and metabolic remodeling, which may provide a new potential therapeutic treatment for RA-related AF.
KeywordsAtrial fibrillation Atrial remodeling Fibrosis Apoptosis Rheumatoid arthritis Resveratrol
AMP-activated protein kinase
Atrial effective refractory period
Bcl-2-associated X Protein
B cell lymphoma-2
Fatty acid translocase/cluster of differentiation 36
Free fatty acid
Glucose transporter 4
PPAR co-activator 1α
Tumor necrosis factor-α
Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling
Y. Z. and S. Z. designed and conducted the experiments, analyzed the data and wrote the manuscript. Y. Z., S. Z., Z. H. L., X. B. Z., Y. Y., and L. S. conducted the experiments. Y. L. designed the experiment and revised the manuscript. All authors approved the final version of the manuscript.
This work was financially supported by grants from the National Nature Scientific Foundation of China (no.81300133, no.81470462).
Compliance with ethical standards
All the protocols conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (the 8th Edition, NRC 2011) and were approved by the Experimental Animals Ethics Committee in Harbin Medical University.
Conflicts of interest
The authors declare that they have no conflict of interest.
- Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285CrossRefGoogle Scholar
- Chong E, Chang SL, Hsiao YW, Singhal R, Liu SH, Leha T, Lin WY, Hsu CP, Chen YC, Chen YJ, Wu TJ, Higa S, Chen SA (2015) Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K/AKT/eNOS signaling pathway activation. Heart Rhythm 12:1046–1056CrossRefGoogle Scholar
- Harada M, Tadevosyan A, Qi X, Xiao J, Liu T, Voigt N, Karck M, Kamler M, Kodama I, Murohara T, Dobrev D, Nattel S (2015) Atrial fibrillation activates AMP-dependent protein kinase and its regulation of cellular calcium handling: potential role in metabolic adaptation and prevention of progression. J Am Coll Cardiol 66:47–58CrossRefGoogle Scholar
- Li Y, Shi J, Yang BF, Liu L, Han CL, Li WM, Dong DL, Pan ZW, Liu GZ, Geng JQ, Sheng L, Tan XY, Sun DH, Gong ZH, Gong YT (2012) Ketamine-induced ventricular structural, sympathetic and electrophysiological remodelling: pathological consequences and protective effects of metoprolol. Br J Pharmacol 165:1748–1756CrossRefGoogle Scholar
- Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343:1594–1602CrossRefGoogle Scholar
- Liu GZ, Hou TT, Yuan Y, Hang PZ, Zhao JJ, Sun L, Zhao GQ, Zhao J, Dong JM, Wang XB, Shi H, Liu YW, Zhou JH, Dong ZX, Liu Y, Zhan CC, Li Y, Li WM (2016) Fenofibrate inhibits atrial metabolic remodelling in atrial fibrillation through PPAR-α/sirtuin 1/PGC-1α pathway. Br J Pharmacol 173:1095–1109CrossRefGoogle Scholar
- National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Source 8th edition. Washington (DC): National Academies Press (US); 2011Google Scholar
- Sun L, Zhang S, Yu C, Pan Z, Liu Y, Zhao J, Wang X, Yun F, Zhao H, Yan S, Yuan Y, Wang D, Ding X, Liu G, Li W, Zhao X, Liu Z, Li Y (2015) Hydrogen sulfide reduces serum triglyceride by activating liver autophagy via the AMPK-mTOR pathway. Am J Physiol Endocrinol Metab 309:E925–E935CrossRefGoogle Scholar